Efficacy News and Research

RSS

Study reveals the potential of novel antiviral drug combinations to stop COVID-19 spread

Researchers from Columbia Engineering, Fiocruz's Center for Technological Development in Health and the Oswaldo Cruz Institute in Brazil, Memorial Sloan Kettering Cancer Center, and Rockefeller University recently reported that, by combining inhibitors of polymerases and exonucleases--enzymes that allow SARS-CoV-2 to reproduce--they were able to reduce SARS-CoV-2 replication 10 times more than when using just the polymerase inhibitors.

7 Mar 2022

SARS-CoV-2 breakthrough infection leads to distinct neutralizing antibody response

Scientists hypothesize that antibody-specific responses vary during vaccine breakthrough infections in a variant-specific manner.

7 Mar 2022

New treatment strategy makes pancreatic tumors sensitive to immunotherapy, mice study shows

Pancreatic cancer is one of the most aggressive and deadly tumor types and notorious for its resistance to virtually all types of treatment, including newer immunotherapies.

7 Mar 2022

Clinical outcomes of regdanvimab usage in patients with mild to moderate COVID-19

Researchers evaluated the effectiveness of regdanvimab on clinical outcomes in patients with mild to moderate COVID-19.

7 Mar 2022

Study offers new hope for patients coping with spinal cord injuries

By employing artificial intelligence (AI) and robotics to formulate therapeutic proteins, a team led by Rutgers researchers has successfully stabilized an enzyme able to degrade scar tissue resulting from spinal cord injuries and promote tissue regeneration.

7 Mar 2022

Current progress in SARS-CoV-2 vaccine candidates

In a new study, researchers illustrated the current progress and obstacles in COVID-19 vaccine development.

7 Mar 2022

Reduced cognitive efficacy and cardiovascular changes in patients post-COVID-19 recovery

Researchers evaluated the association between cognitive impairment and clinical-functional variables in the coronavirus disease 2019 post-acute period.

7 Mar 2022

Patients divided over Alzheimer’s drug: Is it a ‘risk I’m willing to take’ or just a ‘magic pill’?

If you listen to the nation's largest Alzheimer's disease advocacy organizations, you might think everyone living with Alzheimer's wants unfettered access to Aduhelm, a controversial new treatment.

7 Mar 2022

Binding efficacy of SARS-CoV-2 S1 specific salivary antibodies to the Omicron and Delta variants

A recent study assessed the varying affinities of SARS-CoV-2 antibodies to the SARS-CoV-2 Omicron and Delta variants of concern in vaccinated and convalescent individuals.

7 Mar 2022

Combating COVID cytokine storm with targeted nucleic acid therapies

Researchers examine current nucleic acid-based treatments against COVID-19 and their methods of action.

6 Mar 2022

Microneedle treatments could significantly desensitize people with food allergies

Treating peanut allergy with microneedles could significantly improve desensitization by directly targeting the allergen to the skin, providing greater protection from severe allergic reactions for millions of people, a new study suggests.

4 Mar 2022

Long-acting monoclonal antibody shows potential to offer RSV protection for all infants

Nirsevimab showed 74.5 percent efficacy against medically attended lower respiratory tract infections caused by respiratory syncytial virus (RSV) in healthy infants, according to an international, randomized, placebo-controlled Phase 3 clinical trial.

3 Mar 2022

Clinical trial report endorses nitazoxanide as a safe drug for moderately ill COVID-19 patients

Researchers tested the safety and efficacy of 600 mg oral dose of nitazoxanide in mild or moderately ill COVID-19 patients.

3 Mar 2022

8G3 broad-spectrum antibody effective against all SARS-CoV-2 variants, including Omicron

Researchers assess the efficacy of 8G3, a B-cell neutralizing antibody against SARS-CoV-2 variants, including the most recent Omicron variant.

3 Mar 2022

Incidence and outcomes of breakthrough SARS-CoV-2 infections in vaccinated chronic liver disease patients

A new study assesses breakthrough SARS-CoV-2 infections in vaccinated CLD patients with cirrhosis as compared to CLD patients without cirrhosis.

3 Mar 2022

$The benefits of using fractional doses of COVID-19 vaccines$

Efficacy News and Research

Study reveals the potential of novel antiviral drug combinations to stop COVID-19 spread

SARS-CoV-2 breakthrough infection leads to distinct neutralizing antibody response

New treatment strategy makes pancreatic tumors sensitive to immunotherapy, mice study shows

Clinical outcomes of regdanvimab usage in patients with mild to moderate COVID-19

Study offers new hope for patients coping with spinal cord injuries

Current progress in SARS-CoV-2 vaccine candidates

Reduced cognitive efficacy and cardiovascular changes in patients post-COVID-19 recovery

Patients divided over Alzheimer’s drug: Is it a ‘risk I’m willing to take’ or just a ‘magic pill’?

Binding efficacy of SARS-CoV-2 S1 specific salivary antibodies to the Omicron and Delta variants

Combating COVID cytokine storm with targeted nucleic acid therapies

Microneedle treatments could significantly desensitize people with food allergies

Long-acting monoclonal antibody shows potential to offer RSV protection for all infants

Clinical trial report endorses nitazoxanide as a safe drug for moderately ill COVID-19 patients

8G3 broad-spectrum antibody effective against all SARS-CoV-2 variants, including Omicron

Incidence and outcomes of breakthrough SARS-CoV-2 infections in vaccinated chronic liver disease patients

The benefits of using fractional doses of COVID-19 vaccines

Infection with Omicron sub-lineage BA.1 protects from reinfection against BA.2 sub-lineage and vice-versa

Additional doses of covid-19 vaccine recommended for immunocompromised patients

Identifying and managing drug-drug interactions key to the safe use of nirmatrelvir–ritonavir in COVID-19 treatment

How effective is mRNA vaccination in multiple myeloma patients?

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News